Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	445.61M
Revenue (ttm)	7.57M
Net Income (ttm)	-40.71M
Shares Out	5.53M
EPS (ttm)	-7.69
PE Ratio	n/a
Forward PE	186.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,862
Average Volume	9,321
Open	81.00
Previous Close	80.60
Day's Range	79.00 - 81.00
52-Week Range	31.20 - 84.80
Beta	0.71
RSI	61.28
Earnings Date	Apr 2, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 91
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2024, WSE:CTX's revenue was 15.83 million, an increase of 19.88% compared to the previous year's 13.20 million. Losses were -38.43 million, -45.56% less than in 2023.